Canadian Chronic Airway Disease Network (CCADN)

CCADN combines two existing networks: AllerGen Clinical Investigator Collaborative (CIC) and Canadian Cohort Obstructive Lung Disease (CanCOLD) network. Allergen which began in 2008 includes six Canadian universities (McMaster, Quebec, Calgary, Saskatoon, Edmonton, and UBC) funded by the AllerGen Network of Centers of Excellence (NCE), to investigate new treatments for asthma. To date, CIC completed 34 early-phase clinical trials. Its successes include the identification of Tezepelumab, an anti TSLP mAB, recently approved for severe asthma. CanCOLD which began in 2009 includes nine universities (McGill, Quebec, Ottawa, Kingston, Toronto, Saskatoon, Calgary, Vancouver, and Halifax), funded through support from governments (FRQS, CIHR, and Foundations) and global pharmaceutical companies attracting support for a total of $15M, and the only network on COPD in Canada. Its successes are measured in its high number of ancillary studies (~75) and peer reviewed publications (~60) but as importantly, by substantive knowledge translation into clinical practice, in national (CTS) and international (GOLD) guidelines, and into health policies for the benefit of COPD patients.

The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.